Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Interest & Investment Income (2016 - 2025)

Sangamo Therapeutics (SGMO) has disclosed Interest & Investment Income for 14 consecutive years, with $252000.0 as the latest value for Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 14.86% year-over-year to $252000.0; the TTM value through Dec 2025 reached $1.3 million, down 13.95%, while the annual FY2025 figure was $1.3 million, 13.95% down from the prior year.
  • Interest & Investment Income hit $252000.0 in Q4 2025 for Sangamo Therapeutics, down from $355000.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $3.7 million in Q4 2022 and bottomed at $252000.0 in Q4 2025.
  • Average Interest & Investment Income over 5 years is $1.4 million, with a median of $1.1 million recorded in 2021.
  • Year-over-year, Interest & Investment Income surged 145.38% in 2023 and then tumbled 90.04% in 2024.
  • Sangamo Therapeutics' Interest & Investment Income stood at $2.3 million in 2021, then soared by 57.45% to $3.7 million in 2022, then crashed by 59.43% to $1.5 million in 2023, then plummeted by 80.16% to $296000.0 in 2024, then fell by 14.86% to $252000.0 in 2025.
  • According to Business Quant data, Interest & Investment Income over the past three periods came in at $252000.0, $355000.0, and $386000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.